Loading interface...

Cladrim Injection

Manufactured byFRESENIUS KABI INDIA PVT. LTD
ContainsCladribine
Description

Cladrim Injection is used for the treatment of hairy cell leukemia, a rare type of cancer of the blood in which the bone marrow produces excess abnormal B lymphocytes. Close monitoring of kidney function and the blood cell count is necessary while receiving this medication.

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now

Side effects

Major & minor side effects for Cladrim Injection

  • Skin rash
  • Headache
  • Nausea
  • Vomiting
  • Blood in urine
  • Fever
  • Pinpoint red spots on skin
  • Black or Tarry stools
  • Fast heartbeat
  • Constipation
  • Diarrhea
  • Dizziness
  • Muscle or joint pain
  • Stomach pain

Uses of Cladrim Injection

What is it prescribed for?

  • Hairy Cell Leukemia
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time required for this medicine to show its action is not clinically established.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. The risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the medicine based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to cladribine or any other inactive ingredient present along with it.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. The risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the medicine based on your clinical condition.
General warnings

Liver impairment

This medicine should be used with extreme caution in patients suffering from liver diseases due to the increased risk of worsening of the patient's condition. Close monitoring of liver function is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.

Kidney impairment

This medicine should be used with extreme caution in patients suffering from kidney diseases due to the increased risk of worsening of the patient's condition. Close monitoring of kidney function is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.

Risk of infections

Use of this medicine may weaken the immune system and may make you more vulnerable to infections. It is advised that you avoid coming in contact with people suffering from an infection while receiving this medicine.

Driving or operating machinery

Use of this medicine may cause dizziness, tiredness, etc. in some patients. Hence, it is advised that you do not perform any activities that require high mental alertness such as driving a vehicle or operating heavy machinery if you experience any of these symptoms during treatment with this medicine.

Use in children

This medicine is not recommended for use in patients less than 18 years of age since the safety and efficacy of use are not clinically established.

Missed Dose

Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low. If you miss any scheduled session, contact your doctor immediately for further instructions.

Overdose

Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Leflunomide

Live attenuated vaccines and related products

Ganciclovir

Lamivudine

Clozapine

Disease interactions

Bone marrow suppression

This medicine should be used with caution in patients having conditions like thrombocytopenia, agranulocytosis, anemia, or bone marrow suppression due to the increased risk of worsening of the patient's condition. A complete blood count should be performed before initiating treatment with this medicine. Close monitoring of blood counts is recommended during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Neurological disorder

This medicine should be used with extreme caution in patients with neurological impairment due to the increased risk of worsening of the patient's condition. Close monitoring of the clinical condition, appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Liver Disease

This medicine should be used with extreme caution in patients suffering from liver diseases due to the increased risk of worsening of the patient's condition. Close monitoring of liver function is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.

Kidney Disease

This medicine should be used with extreme caution in patients suffering from kidney diseases due to the increased risk of worsening of the patient's condition. Close monitoring of kidney function is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.
Food interactions
Information not available.
Lab interactions
Information not available.
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.
Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

Does not cause sleepiness

How it works
This medicine prevents the growth and spread of cancer cells in the body.
Legal Status

Approved

Unknown

Approved

Approved

Classification

Category

Antimetabolites, Antineoplastics

Schedule

Schedule H

[Internet]. Drugbank.ca. 2018 [cited 13 December 2018]. Available from:

https://www.drugbank.ca/drugs/DB00242

[Internet]. Pubchem.ncbi.nlm.nih.gov. 2018 [cited 13 December 2018]. Available from:

https://pubchem.ncbi.nlm.nih.gov/compound/Cladribine

[Internet]. Medlineplus.gov. 2018 [cited 13 December 2018]. Available from:

https://medlineplus.gov/druginfo/meds/a693015.html

[Internet]. Accessdata.fda.gov. 2018 [cited 13 December 2018]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020229s034lbl.pdf

Leustat Injection. - Summary of Product Characteristics (SmPC) - (eMC) [Internet]. Medicines.org.uk. 2019 [cited 19 April 2019]. Available from:

https://www.medicines.org.uk/emc/product/1438/smpc
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 19 Apr 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.